Avidity Biosciences (NASDAQ:RNA) Earns Sector Outperform Rating from Analysts at Scotiabank
Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, MarketBeat Ratings reports. The brokerage issued a sector outperform rating and a $70.00 target price on the biotechnology company’s stock. Other analysts also recently issued research reports about the company. Chardan Capital reaffirmed a “buy” rating […]
Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, MarketBeat Ratings reports. The brokerage issued a sector outperform rating and a $70.00 target price on the biotechnology company’s stock. Other analysts also recently issued research reports about the company. Chardan Capital reaffirmed a “buy” rating […]
